SCLP.L

Scancell Holdings plc [SCLP.L] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

SCLP.L Stock Summary

Top 10 Correlated ETFs

SCLP.L

Top 10 Correlated Stocks

SCLP.L

In the News

SCLP.L Financial details

Company Rating
-
Market Cap
93.73M
Income
-19.76M
Revenue
5.27M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
51
Optionable
No
Shortable
Yes
Earnings
30 Jan 2024
P/E
-7.61
Forward P/E
-
PEG
-0.09
P/S
19.58
P/B
-14.57
P/C
-
P/FCF
-12.37
Quick Ratio
6.08
Current Ratio
7.51
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.02
EPS next Y
-
EPS next Q
-
EPS this Y
484%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-71.03%
-
-
-
-
SMA20
36.35%
SMA50
21.3%
SMA100
-16.43%
Inst Own
-
Inst Trans
-
ROA
-39%
ROE
-180%
ROC
-0.44%
Gross Margin
90%
Oper. Margin
-226%
Profit Margin
-226%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
7.585-20.9918
52W High
-46.25%
52W Low
+53.57%
RSI
60.68
Rel Volume
1.99
Avg Volume
440.06K
Volume
877.35K
Perf Week
2.38%
Perf Month
26.47%
Perf Quarter
-19.66%
Perf Half Y
-25.86%
-
-
-
-
Beta
0.341
-
-
Volatility
0.32%, 1.4%
Prev Close
0%
Price
10.75
Change
-6.52%

Something similar

Top by Market Cap
NVDA
ABEC.DE
LLY.SW
FXAIX
BRYN.DE
Top Correlated ETFs
IPRP.L
IGEA.L
SUA0.DE
TCBT.DE
IGAA.L
Top Correlated Stocks
GREEN.BR
READ.ST
TOTS3.SA
CEK.DE
3939.HK
Similar Market Cap
XRTX
ROOT.TO
ZICOM.NS
NSI.L
CSMXCP.SW

Company Profile

Healthcare Biotechnology
  • Volume Average 440.06K
  • Market Capitalization 93.73M
  • Employee 51
  • CEO Prof. Lindy Gillian Durrant Ph.D.
  • Headquarters Oxford,GB
  • IPO Date 2010-02-12
  • Website https://www.scancell.co.uk

Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 for the treatment of non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a prophylactic DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.